Shenqi(SH:600613) Feng Huang Wang·2025-09-26 12:44Core Viewpoint - The company, Shenqi Pharmaceutical, has been subjected to administrative regulatory measures by the Shanghai Securities Regulatory Bureau due to irregularities in its accounting practices, specifically related to the handling of accounts receivable and the misrepresentation of financial information in its 2023 annual report [1][2]. Group 1: Regulatory Actions - Shenqi Pharmaceutical received a decision from the Shanghai Securities Regulatory Bureau, which includes a directive for corrective measures and warnings issued to key executives for their lack of diligence [1][2]. - The company is required to submit a written rectification report within 30 days and is committed to improving its accounting practices to prevent future occurrences [2]. Group 2: Financial Performance - In the first half of 2025, Shenqi Pharmaceutical reported a decline in both revenue and net profit, with operating income of 961 million yuan, a year-on-year decrease of 13.47%, and a net profit attributable to shareholders of 32.81 million yuan, down 13.29% [3]. - The net cash flow from operating activities decreased by 75.44 million yuan, representing a decline of 61.38%, primarily due to reduced sales and slower collection of receivables [3]. Group 3: Company Overview - Shenqi Pharmaceutical, listed since August 20, 1992, specializes in the research, production, and sales of pharmaceuticals, with key products including anti-tumor drugs and various traditional Chinese medicine formulations [2].